ストックスクリーナーアプリを入手
6.62
0.90%
-0.06
アフターアワーズ：
6.49
-0.13
-1.96%
Diamedica Therapeutics Inc (DMAC) 最新ニュース
All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy - Yahoo Finance
What is HC Wainwright's Estimate for DMAC Q3 Earnings? - marketbeat.com
DiaMedica Therapeutics Inc. (DMAC) stock price, news, quote and history - Yahoo Finance UK
DiaMedica Therapeutics (DMAC) CEO receives 60,200 RSU award vesting over four years - Stock Titan
DiaMedica Therapeutics Inc (DMAC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ... - Yahoo Finance
DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highli - GuruFocus
DiaMedica Expands Equity Incentive Pool With New S-8 Share Registration - TipRanks
DiaMedica Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
DiaMedica Therapeutics (DMAC) Advances Clinical Trials Amid High Price-to-Sales Valuation - GuruFocus
DiaMedica Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
DMAC Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus
HC Wainwright Reaffirms Buy Rating for DiaMedica Therapeutics (NASDAQ:DMAC) - marketbeat.com
DiaMedica Therapeutics Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: DiaMedica Q2 2026 loss matches forecast as trials advance - Investing.com
DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ... By GuruFocus - Investing.com Canada
DiaMedica Therapeutics Reports Q2 2026 Form 10-Q Highlighting Clinical Trial Enrollment Challenges - Kalkine Media
DiaMedica Advances Key Phase 2 Programs and Extends Cash Runway Through 2027 - TipRanks
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - biospace.com
DiaMedica Therapeutics (DMAC) Reports Positive Interim Data, Mar - GuruFocus
DiaMedica Q2 net loss widens to $10.1M as DM199 shows clinical promise - scanx.trade
DiaMedica Therapeutics (NASDAQ:DMAC) Issues Quarterly Earnings Results - marketbeat.com
DiaMedica Therapeutics reports Q2 net loss $10.1M, cash $43.5M; advances DM199 clinical programs - TradingView
DiaMedica reports $10.1 million Q2 loss as DM199 trials advance - Quiver Quantitative
DiaMedica Therapeutics (NASDAQ: DMAC) increases R&D spend and loss in Q2 2026 - Stock Titan
DiaMedica Therapeutics Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
DiaMedica Therapeutics Inc (DMAC) Stock News Today - TradingKey
(DMAC) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Press Release: DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights - 富途牛牛
Press Release: DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 - Moomoo
DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 - Business Wire
DiaMedica Therapeutics (DMAC) Expected to Post Earnings on Tuesday - marketbeat.com
1 Main Capital Highlights DiaMedica Therapeutics in Q2 2026 Letter - sekbernews.id
DiaMedica Therapeutics (DMAC): BioTech with Breakthrough Potential - Yahoo Finance
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Rating of "Moderate Buy" by Brokerages - marketbeat.com
DiaMedica Therapeutics Inc (DMAC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
DiaMedica Therapeutics (NASDAQ:DMAC) Trading Down 1.5%Should You Sell? - MarketBeat
DMAC|DiaMedica Therapeutics Inc|Price:6.720|Chg%:-0.015 - TradingKey
DiaMedica Therapeutics Inc. Revenue Breakdown – NASDAQ:DMAC - TradingView
DiaMedica Therapeutics Inc (DMAC) Income Statement - TradingKey
DiaMedica Therapeutics Inc (DMAC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
DiaMedica Therapeutics Inc (DMAC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
DiaMedica Therapeutics Market Sentiment - Benzinga España
DiaMedica Therapeutics Inc (DMAC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
DMAC|DiaMedica Therapeutics Inc|Price:6.680|Chg%:-0.070 - TradingKey
DiaMedica Therapeutics Inc (DMAC) Cash Flow - TradingKey
DiaMedica Therapeutics Inc (DMAC) Balance Sheet - TradingKey
DMAC|DiaMedica Therapeutics Inc|Price:6.588|Chg%:-0.162 - TradingKey
DiaMedica Therapeutics Inc (DMAC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price to book forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView
$7.37 | DiaMedica Therapeutics Inc. Common Stock (DMAC) Stock Price Today - Binance
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
(DMAC) Risk Channels and Responsive Allocation - Stock Traders Daily
DiaMedica Therapeutics (DMAC) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
DMAC Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Yield Spread - DonanımHaber
DMAC PE Ratio & Valuation, Is DMAC Overvalued - Intellectia AI
Enterprise value to EBITDA forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView
DiaMedica Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Enterprise value to revenue forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView
Price to sales forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView
DMAC Q1 2026 Earnings: EPS Misses Estimates as Clinical Pipeline AdvancesEarnings Growth Forecast - dars.gov.et
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
DiaMedica Therapeutics Inc. Actuals & Estimates (NASDAQ:DMAC) - TradingView
DMAC Forecast — Price Target — Prediction for 2027 - TradingView
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):